{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:54:04Z","timestamp":1793836444217,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Chronic Hypersensitivity Pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from repeated exposure to an offending antigen. Prognostication in cHP remains challenging, and the relationship between comorbidities and survival has yet to be characterized. The aim of this study was to describe the relationship between comorbid conditions and survival in patients with cHP.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The prospective database from a tertiary referral centre for ILD was reviewed for patient-reported comorbidities, their frequency, and relationship with survival in cHP patients. Comorbidities were assessed by direct questioning of the patient at the baseline visit and by a standardized questionnaire for the diagnosis of interstitial lung diseases. During the follow-up examinations, patients were asked about newly diagnosed comorbidities.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Two hundred eleven patients with cHP were identified (mean age 63\u2009years, 53% male, mean FVC 73%), with mean follow-up of 32\u2009months. The mean number of comorbidities was 3 (10% had 0, 59% 1\u20133 and 31% \u22654 comorbidities). Most frequent comorbidities groups were cardiovascular (65%) and respiratory (26%), most common comorbidities were hypertension (56%), gastro-esophageal reflux disease (GERD) (24%), diabetes (20%) and coronary heart disease (18%). In general, deceased patients had more comorbidities than survivors (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), yet there was no association between the absolute number of comorbidities and survival. Pulmonary hypertension (30.8% versus 5.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.001;), diastolic dysfunction (26.9% versus 6.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and cerebrovascular disease were more frequent in non-survivors (23.1% versus 7.6%, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). Lung cancer was not observed, and neither GERD nor antacid drugs were associated with outcome (<jats:italic>p<\/jats:italic>\u2009=\u20090.357 and <jats:italic>p<\/jats:italic>\u2009=\u20090.961, respectively).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Comorbidities are common in cHP are associated with survival. Further work should determine whether interventions for these specific comorbidities can positively affect survival.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-1283-8","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T16:02:27Z","timestamp":1578585747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Comorbidities and survival in patients with chronic hypersensitivity pneumonitis"],"prefix":"10.1186","volume":"21","author":[{"given":"Julia","family":"W\u00e4lscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri A.","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vasakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bruhwyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"issue":"1","key":"1283_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5858\/arpa.2017-0173-RA","volume":"142","author":"A Churg","year":"2018","unstructured":"Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis what is it? What are the diagnostic criteria? Why do we care? Arch Pathol Lab Med. 2018;142(1):109\u201319.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"1283_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1164\/rccm.201203-0513CI","volume":"186","author":"M Selman","year":"2012","unstructured":"Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314\u201324.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1283_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","volume":"4","author":"SLF Walsh","year":"2016","unstructured":"Walsh SLF, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med. 2016;4(7):557\u201365.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1283_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S2213-2600(13)70191-7","volume":"1","author":"F Morell","year":"2013","unstructured":"Morell F, Villar A, Montero MA, Munoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med. 2013;1(9):685\u201394.","journal-title":"Lancet Respir Med"},{"issue":"128","key":"1283_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09059180.00000813","volume":"22","author":"V Cottin","year":"2013","unstructured":"Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013;22(128):153\u20137.","journal-title":"Eur Respir Rev"},{"issue":"10","key":"1283_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.amjmed.2003.12.030","volume":"116","author":"JS Vourlekis","year":"2004","unstructured":"Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med. 2004;116(10):662\u20138.","journal-title":"Am J Med"},{"issue":"10","key":"1283_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2169\/internalmedicine.34.966","volume":"34","author":"Y Ohtsuka","year":"1995","unstructured":"Ohtsuka Y, Munakata M, Tanimura K, Ukita H, Kusaka H, Masaki Y, et al. Smoking promotes insidious and chronic farmer\u2019s lung disease, and deteriorates the clinical outcome. Intern Med. 1995;34(10):966\u201371.","journal-title":"Intern Med"},{"issue":"3","key":"1283_CR8","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with Idiopathic Pulmonary Fibrosis. PLoS One. 2016;11(3):e0151425.","journal-title":"PLoS One"},{"issue":"5","key":"1283_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1183\/13993003.01482-2016","volume":"48","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, et al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Eur Respir J. 2016;48(5):1524\u20136.","journal-title":"Eur Respir J"},{"issue":"1","key":"1283_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-018-0769-0","volume":"19","author":"L Schwarzkopf","year":"2018","unstructured":"Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Respir Res. 2018;19(1):73.","journal-title":"Respir Res"},{"key":"1283_CR11","doi-asserted-by":"crossref","unstructured":"Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, et al. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi survey. Am J Respir Crit Care Med. 2018;197(8):1036-1044.","DOI":"10.1164\/rccm.201710-1986OC"},{"issue":"6","key":"1283_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1055\/s-0044-100207","volume":"72","author":"M Kreuter","year":"2018","unstructured":"Kreuter M, Ochmann U, Koschel D, Behr J, Bonella F, Claussen M, et al. DGP interstitial lung disease patient questionnaire. Pneumologie. 2018;72(6):446\u201357.","journal-title":"Pneumologie"},{"issue":"4","key":"1283_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.13-1474","volume":"145","author":"CJ Ryerson","year":"2014","unstructured":"Ryerson CJ, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723\u20138.","journal-title":"Chest"},{"issue":"3","key":"1283_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00408-011-9361-9","volume":"190","author":"DS Koschel","year":"2012","unstructured":"Koschel DS, Cardoso C, Wiedemann B, Hoffken G, Halank M. Pulmonary hypertension in chronic hypersensitivity pneumonitis. Lung. 2012;190(3):295\u2013302.","journal-title":"Lung"},{"issue":"2","key":"1283_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pcad.2012.07.006","volume":"55","author":"H El Chami","year":"2012","unstructured":"El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012;55(2):218\u201328.","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"1283_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of Pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903\u201375.","journal-title":"Eur Respir J"},{"issue":"18","key":"1283_CR17","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","volume":"379","author":"M Kolb","year":"2018","unstructured":"Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al. Nintedanib plus sildenafil in patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;379(18):1722\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"1283_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1002110","volume":"363","author":"DA Zisman","year":"2010","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"1283_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","volume":"190","author":"TJ Corte","year":"2014","unstructured":"Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190(2):208\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1283_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3346\/jkms.2012.27.7.756","volume":"27","author":"YJ Kim","year":"2012","unstructured":"Kim YJ, Park JW, Kyung SY, Lee SP, Chung MP, Kim YH, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci. 2012;27(7):756\u201360.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1283_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000488909","volume":"96","author":"S Kopf","year":"2018","unstructured":"Kopf S, Groener JB, Kender Z, Fleming T, Brune M, Riedinger C, et al. Breathlessness and restrictive lung disease: an important diabetes-related feature in patients with type 2 diabetes. Respiration. 2018;96(1):29\u201340.","journal-title":"Respiration"},{"issue":"1 Suppl","key":"1283_CR22","doi-asserted-by":"publisher","first-page":"71S","DOI":"10.1378\/chest.120.1_suppl.S71","volume":"120","author":"J Usuki","year":"2001","unstructured":"Usuki J, Enomoto T, Azuma A, Matsuda K, Aoyama A, Kudoh S. Influence of hyperglycemia to the severity of pulmonary fibrosis. Chest. 2001;120(1 Suppl):71S.","journal-title":"Chest."},{"issue":"3","key":"1283_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","volume":"151","author":"J Morisset","year":"2017","unstructured":"Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, et al. Use of Mycophenolate Mofetil or azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2017;151(3):619\u201325.","journal-title":"Chest"},{"issue":"4","key":"1283_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000489668","volume":"96","author":"P Spagnolo","year":"2018","unstructured":"Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, et al. Metformin does not affect clinically relevant outcomes in patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018;96(4):314\u201322.","journal-title":"Respiration"},{"issue":"4","key":"1283_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1183\/09031936.00102107","volume":"31","author":"CE Papadopoulos","year":"2008","unstructured":"Papadopoulos CE, Pitsiou G, Karamitsos TD, Karvounis HI, Kontakiotis T, Giannakoulas G, et al. Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic [corrected] study. Eur Respir J. 2008;31(4):701\u20136.","journal-title":"Eur Respir J"},{"issue":"3","key":"1283_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/thoraxjnl-2013-203740","volume":"69","author":"V Navaratnam","year":"2014","unstructured":"Navaratnam V, Fogarty AW, McKeever T, Thompson N, Jenkins G, Johnson SR, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax. 2014;69(3):207\u201315.","journal-title":"Thorax"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-1283-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-1283-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:51:10Z","timestamp":1610067070000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-1283-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-1283-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"27 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the University of Heidelberg approved this retrospective study. (S-318\/2013).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JW received personal fees from Boehringer Ingelheim und Roche.MK received research grants and personal fees from Boehringer Ingelheim und Roche.JB received fees from the German Center for Lung Research, Heidelberg, Germany, and was responsible for the statistical analyses.The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}